Celgene CC-4047-MM-007 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Cancer - Hematology/ Blood

18 years or older with a diagnosis of Multiple Myeloma; at least 1 but no greater than 3 prior anti-myeloma treatment regimens; disease progression during or after the last anti-myeloma therapy; must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.

Tiffany Pearce